Vertex to Pause Some Clinical Trials Due to COVID-19

March 27, 2020

Vertex Pharmaceuticals said that it has made changes to some of its ongoing and planned clinical trials due to COVID-19, including pausing enrollment for some trials.

The drugmaker is working with sites to allow virtual clinic visits and home delivery of study drugs to ensure study continuity and medical monitoring. However, it will temporarily hold enrollment for certain studies depending on the disease, stage of development and type of study.

Vertex said that the outbreak has not had any impact on its supply chain for approved medicines and that its manufacturing facilities are operating during the pandemic.

View today's stories